Anti-COVID-19 Antibodies & Proteins in Development
This Competitive Intelligence report about Anti-COVID-19 Antibodies & Proteins in Development describes the landscape of industry-driven approaches to discover and develop therapeutic antibodies and proteins for treatment of COVID-19 as of April 6, 2020.
COVID-19 is caused by SARS-CoV-2, which belongs to a group of viruses called coronaviruses that attack the respiratory system. There is currently no licensed vaccine, treatment or cure for COVID-19. Since the outbreak of the SARS-CoV-2 pandemia, industry efforts rapidly have initiated work to repurpose existing biologic therapeutics and discover and develop antibody and protein candidates to treat COVID-19 based on a variety of approaches, including
- Therapeutic Antibodies & Proteins for Immunomodulation of COVID-19
- Plasma Immunoglobulins for Treatment of COVID-19
- Biologic Antivirals
- Recombinant SAR-CoV-2 Neutralizing Antibodies
- DNA & mRNA anti-SARS-CoV-2 Antibodies
Clinical evaluation of the first repurposed biologics and plasma-derived immunoglobulins has begun and a total at least 34 vaccine approaches to prevent COVID-19 are in the pipeline.
This report includes a compilation of industry-driven projects in research and development of SARS-CoV-2 targeted antibodies and proteins for treatment of COVID-19. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Product Category,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.